Clinical evaluation of the efficacy and safety of paroxetin in poststroke depression: Results from a phase 4, open label, multicentre clinical trial with 26 weeks of follow-up;A paroxetin klinikai hatékonysága és biztonságossága stroke-ot követo depresszióban: 4. Fázisú multicentrikus, nyílt, 26 hetes utánkövetéses klinikai vizsgálat eredményei

Orvosi Hetilap

Volumn 147, Issue 50, 2006, Pages 2397-2404

  Horváth, Sándor ^a   Karányi, Zsolt ^b   Harcos, Péter ^a   Nagy, Zoltán ^a   Németh, György ^a   Andor, György ^a  

^a Neurológiai Osztály ^*  (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Clinical trial; Paroxetin; Poststroke depression; Therapy

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; SCORING SYSTEM; STROKE; SYMPTOM; ADULT; CEREBROVASCULAR ACCIDENT; DAILY LIFE ACTIVITY; HUNGARY; MIDDLE AGED; PREVALENCE; PSYCHOLOGICAL ASPECT; TIME; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CEREBROVASCULAR ACCIDENT; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNGARY; MALE; MIDDLE AGED; PAROXETINE; PREVALENCE; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247873070     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Andersen, G., Vestergaard, K., Lauritzen, L. U.: Effective treatment of depression following apoplexy with citalopram. Ugeskr. Laeger, 1995, 157, 2000-2003.
2. Benkert, O., Szegedi, A., Kohnen, R.: Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiatry, 2000, 61, 656-663.
3. Burns, A., Russell, E., Stratton-Powell, H. és mtsai: Sertraline in stroke-associated lability of mood. Int. J. Geriatr Psychiatry, 1999, 14, 681-685.
4. Erfurth, A., Loew, M., Wendler, G. és mtsa: Depressive störungen in der neurologischen rehabilitation: therapie mit paroxetin. Psychiatr. Prax., 2001, 28, 43-44.
5. Fruehwald, S., Gatterbauer, E., Rehak, P. és mtsa: Early fluoxetine treatment of post-stroke depression - a three-month double-blind placebo-controlled study with an open-label long-term follow up. J. Neurol., 2003, 250, 347-351.
6. Hackett, D., Haudiquet, V, Salinas, E.: A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur. Psychiatry, 2003, 18, 182-187.
7. Jorge, R. E., Robinson, R. G., Arndt, S. és mtsa: Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am. J. Psychiatry, 2003, 160, 1823-1829.
8. Katayama, Y., Usuda, K., Nishiyama, Y. és mtsa: Post-stroke depression. Nippon Ronen Igakkai Zasshi, 2003, 40, 127-129.
9. Morris, P. L., Robinson, R. G., Andrzejewski, P. és mtsai: Association of depression with 10-year poststroke mortality. Am. J. Psychiatry, 1993, 150, 124-129.
10. Murray, V., von Arbin, M., Bartfai, A. és mtsai: Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J. Clin. Psychiatry, 2005, 66, 708-716.
11. Narushima, K., Kosier, J. T., Robinson, R. G.: Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J. Nerv. Ment. Dis., 2002, 190, 296-303.
12. Niklson, I. A., Reimitz, P-E., Sennef, C.: Factors that influence the outcome of placebo-controlled antidepressant trials. Psychopharmacol. Bull., 1997, 33, 41-51.
13. Paolucci, S., Antonucci, G., Grasso, M. G. és mtsai: Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc. Dis., 2001, 12, 264-271.
14. Pohjasvaara, T., Vataja, R., Leppavuori, A. és mtsai: Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur. J. Neurol., 2001, 8, 315-319.
15. Rampello, L., Alvano, A., Chiechio, S. és mtsai: An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch. Gerontol. Geriatr., 2005, 40, 275-285.
16. Rampello, L., Chiechio, S., Nicoletti G. és mtsai: Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl.), 2004, 173, 73-78.
17. Rasmussen, A., Lunde, M., Poulsen, D. L. és mtsai: A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics, 2003, 44, 216-221.
18. Robinson, R. G.: Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol. Psychiatry, 2003, 54, 376-87.
19. Spalletta, G., Caltagirone, C.: Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. Funct. Neurol., 2003, 18, 227-232.
20. Spalletta, G., Guida, G., Caltagirone, C.: Is left stroke a risk-factor for selective serotonin reuptake inhibitor antidepressant treatment resistance? J. Neurol., 2003, 250, 449-455.
21. Stolk, P.: Meta-analysis of placebo rates in major depressive disorder trials. Ann. Pharmacother., 2003, 37, 1891-1899.
22. Van de Meent, H., Geurts, A. C., Van Limbeek, J.: Pharmacologic treatment of poststroke depression: a systematic review of the literature. Top Stroke Rehabil., 2003, 10, 79-92.
23. Wiart, L., Petit, H., Joseph, P. A. és mtsai: Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke, 2000, 31, 1829-1832.
24. Zifko, U. A., Rupp, M., Schwarz, S.: Sertralin in der Behandlung der Post-Stroke-Depression - Ergebnisse einer offenen Multicenterstudie. Wien Med. Wochenschr., 2002, 152, 343-348.